Product Description
Chloroprocaine is an ester class local anesthetic and is indicated for neuraxial anesthesia (caudal, epidural, and spinal) and peripheral nerve blocks and obstetric anesthesia (pudendal and paracervical blocks). Due to its short duration, it has been used in test doses to evaluate the function of peripheral nerve and epidural catheters. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK532901/)
Mechanisms of Action: Voltage-Gated Sodium Channel Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intrathecally
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Bulgaria | Canada | Croatia | Czech | Dominican Republic | Estonia | Finland | France | Germany | Greece | Hungary | Ireland | Israel | Italy | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Sintetica
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy, Spain
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Anesthesia Related
Phase 2: Flatfoot
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CHL.2/04-2015 | P2 |
Unknown Status |
Anesthesia Related |
2025-03-31 |
|
| CHL.3-01-2021-M | P3 |
Recruiting |
Anesthesia Related |
2024-12-31 |
|
| CHL.2/04-2015 | P2 |
Recruiting |
Flatfoot |
2024-12-30 |
|
| CHL.2/04-2015 | P2 |
Active, not recruiting |
Flatfoot |
2020-10-08 |